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Résumé en
anglais
Glioblastoma stem cells correspond to brain tumor-initiating cells (BTICs) that have
been identified in glioblastoma, the most common and aggressive brain tumor, as
responsible for tumor initiation, progression and recurrence due to their resistance to
current treatments. Targeting these cancer stem cells represents a crucial challenge to
develop new therapeutic strategies. Previous works have shown that the NFL-
TBS.40-63 peptide, corresponding to a tubulin-binding site on neurofilaments, targets
and reduces in vitro and in vivo the viability of glioblastoma cells without affecting
healthy cells. The objective of this study is to investigate the effect of this peptide on
BTICs isolated from human glioblastoma. The uptake of this peptide alone or coupled
to nanocapsules was analyzed by flow cytometry and immunochemistry. Its anti-tumor
effect was studied using proliferation, adhesion and viability assays. Peptide-mediated
effects were also evaluated on the BTIC self-renewal ability and by
immunocytochemistry to investigate their cell shape and microtubule network. Here
we show that the peptide enters massively in BTICs and demonstrates an anti-tumor
effect by inhibiting their proliferation and inducing their death through an alteration of
their microtubule network and cell-cell adhesion, and a decrease in the self-renewal
ability of these cancer stem cells. These results indicate that the NFL-TBS.40-63
peptide represents a promising therapeutic drug for glioblastoma treatment by
targeting and killing both glioblastoma cells and BTICs to prevent recurrence.
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